Table 3 Comparison between the non-high-dose and high-dose groups of patients after randomly matched analysis by using Greedy method

Age (years)

65.6 ± 11.8

65.5 ± 13.9

0.258

Female gender, n (%)

24(23.1)

39(37.5)

0.024*

Creatinine(mg/dl)

2.4 ± 2.3

2.8 ± 2.9

0.010*

Hb (g/L)

88.9 ± 25.2

89.1 ± 27.6

0.386

Platelet(× 10⁹/L)

191.5 ± 88.8

198.9 ± 106.3

0.113

Use of NSAIDs, n (%)

9(8.7)

11(10.6)

0.638

Use of aspirin, n (%)

15(14.4)

18(17.3)

0.569

Use of clopidogrel, n (%)

11(10.6)

13(12.5)

0.664

Use of wafarin, n (%)

6(5.8)

10(9.6)

0.298

Shock at presentation

52(50.0)

65(62.5)

0.069

Coexisting illness, n (%)

CKDIII, IV/V

40/14 (38.5/13.5)

40/15(38.5/14.4)

0.978

COPD

7(6.7)

6 (5.8)

0.775

CAD

19(18.3)

28(26.9)

0.136

DM

34(32.7)

39(37.5)

0.468

CVA

21(20.2)

23(22.1)

0.734

Liver Cirrhosis

20(19.2)

14(13.5)

0.261

Rockall score

6.4 ± 1.4

6.4 ± 1.4

1.000

Time to endoscope (h)

16.4 ± 20.3

16.9 ± 19.8

0.482

PRBC BT(mL)

1252.4 ± 1272.1

2156.3 ± 2117.1

0.007

Ulcer size (cm)

1.0 ± 0.6

0.9 ± 0.6

0.901

Multiple ulcers, n (%)

29(27.9)

38(36.5)

0.182

Forrest classification Ia/Ib/IIa/IIb/IIc/III

2/70/6/26/0/0

3/70/6/25/0/0

0.974

Re-bleeding, n (%)

14 (13.5)

34 (32.7)

0.001*

Surgery, n (%)

2(1.9)

1(1.0)

0.561

Hospital stay (days)

13.9 ± 22.3

17.9 ± 15.3

0.641

Mortality, n (%)

10(9.6)

16(15.4)

0.403

Bleeding related/Other causes

4/6

8/8